Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Evaluation of the Palmaz Mach-5 Grooved Bare Metal Coronary Stent System Versus the Palmaz Bare Metal Coronary Stent System in Patients With Symptomatic Ischemic Heart Disease: A Safety and Performance Study

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT02759406
Recruitment Status : Completed
First Posted : May 3, 2016
Last Update Posted : May 3, 2016
Sponsor:
Collaborator:
ClinLogix. LLC
Information provided by (Responsible Party):
Palmaz Scientific

Brief Summary:
This is a six (6) month, randomized, un-blinded, study to assess the safety and performance of the Palmaz Mach-5 Grooved Coronary Stent System vs. the Palmaz Bare Metal Coronary Stent System.

Condition or disease Intervention/treatment Phase
Ischemic Heart Disease Device: coronary stent Not Applicable

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 48 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Evaluation of the Palmaz Mach-5 Grooved Bare Metal Coronary Stent System Versus the Palmaz Bare Metal Coronary Stent System in Patients With Symptomatic Ischemic Heart Disease: A Safety and Performance Study
Study Start Date : September 2013
Actual Primary Completion Date : May 2015
Actual Study Completion Date : June 2015

Resource links provided by the National Library of Medicine


Arm Intervention/treatment
Experimental: Mach-5 Grooved
grooved
Device: coronary stent
Experimental: Mach 5 Bare Metal
bare metal
Device: coronary stent



Primary Outcome Measures :
  1. late lumen loss rate by Quantative/ Qualtative Cornary Angiographia [ Time Frame: 6 month ]
  2. total percentage of strut coverage by Optical Coherence Tomography analysis [ Time Frame: 6 month ]
  3. Primary safety endpoint is the occurrence of adverse events associated with the Investigational and comparator devices. [ Time Frame: 6 month ]
  4. binary restenosis rate by Quantative/ Qualtative Cornary Angiographia [ Time Frame: 6 month ]


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  1. Male or female patients of any race greater than or equal to 18 years and of legal consent
  2. Patients must be willing to comply with the specified follow-up evaluation schedule
  3. Patients who sign an informed consent (signed and dated) prior to any study-related evaluation or procedure.
  4. Patients who are willing to undergo a follow-up coronary angiogram and Endovascular Imaging via Optical Coherence Tomography
  5. Patients willing to be maintained on Aspirin and Clopidogrel bisulfate (Plavix) for ninety (90) days post procedure.
  6. Patients with a de novo coronary lesion causing angina and/or a positive function test
  7. Patients who are eligible for percutaneous coronary interventions
  8. Low risk NSTEMI defined as patients with ACS, unstable angina, positive cardiac biomarkers and hemodynamically stable as assessed by the Investigator.
  9. Patients with an acceptable risk for coronary bypass graft surgery (CABG)

Intra-Procedure Angiographic Criteria:

  1. Single de novo target lesion >50% diameter stenosis by angiography
  2. Single target vessel 2.75 to 3.25 mm diameter
  3. Lesion length of 14 to 20mm which is suitable for Palmaz Mach-5 Grooved Coronary Stent System or the Palmaz Bare Metal Coronary Stent System.

Exclusion Criteria:

  1. Known allergy or sensitivity to cobalt chromium (CoCr) alloy or its components.
  2. Known sensitivity or allergy to aspirin, radiographic contract agents (that cannot be pre-treated adequately).
  3. Patients unable to tolerate anticoagulant therapy or antiplatelet therapy.
  4. History of bleeding or known coagulopathy.
  5. Patients with thrombocytopenia and or neutropenia.
  6. More than one stenosis >50% in target vessel.
  7. Lesion in aortic ostium.
  8. Left main or LAD, CX lesions within 2-mm from the origin.
  9. Ejection Fraction <45%.
  10. STEMI in evolution.
  11. Disabling stroke within previous 30 days.
  12. Patients currently enrolled in another Investigational device or drug study.
  13. Previous enrollment in this study.
  14. Women who are currently pregnant. (A negative pregnancy test for female subjects of child bearing potential is required within 24 hours of procedure.)
  15. Known or suspected active systemic infection.
  16. Evidence of severe or uncontrolled systemic diseases, including chronic renal insufficiency, or any condition which in the Investigator's opinion makes it undesirable for the patient to participate in the trial or which would jeopardize compliance with the protocol.

Layout table for additonal information
Responsible Party: Palmaz Scientific
ClinicalTrials.gov Identifier: NCT02759406     History of Changes
Other Study ID Numbers: Mach-5
First Posted: May 3, 2016    Key Record Dates
Last Update Posted: May 3, 2016
Last Verified: April 2016
Additional relevant MeSH terms:
Layout table for MeSH terms
Heart Diseases
Myocardial Ischemia
Coronary Artery Disease
Ischemia
Pathologic Processes
Cardiovascular Diseases
Vascular Diseases
Coronary Disease
Arteriosclerosis
Arterial Occlusive Diseases